- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
AstraZeneca Gets CDSCO Panel Nod To study COPD Drug Tozorakimab
New Delhi: Pharmaceutical major AstraZeneca has got the green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase II clinical trial of the Chronic Obstructive Pulmonary Disease (COPD) drug Tozorakimab.
This came after the firm presented a study for acute viral infection respiratory failure (ARDS) except for COVID-19 and proposed conducting Phase II study vide protocol no: D9185C00001 version 1.0, 15-sep-2022 and local CSP Addendum IND-1: version 1.0, dated 14-Oct-2022 before the committee.
Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney disease, Coronavirus disease (COVID-19), chronic bronchitis, asthma, acute respiratory failure, and chronic obstructive pulmonary disease (COPD). The drug candidate is administered through a subcutaneous or intravenous route in the form of a solution. It is a monoclonal antibody that acts by targeting the interleukin-33 (IL-33). The drug candidate is a new molecular entity. It was also under development for the treatment of atopic dermatitis
Tozorakimab is a novel therapeutic agent with a dual mechanism of action that blocks IL-33red and IL-33ox signaling, offering the potential to reduce inflammation and epithelial dysfunction in human disease. It develops products related to therapy areas such as respiratory, cardiovascular, renal, and metabolic diseases, cancer, autoimmune, infection, and neurological diseases.
At the recent SEC meeting for Pulmonary held on 10th May 2023, the expert panel reviewed the proposal presented by AstraZeneca for conducting Phase II study vide protocol no: D9185C00001 version 1.0, 15-sep-2022 and local CSP Addendum IND-1: version 1.0, dated 14-Oct-2022 before the committee.
After detailed deliberation, the committee recommended the grant of permission for the conduct of Phase II clinical trial as presented by the firm.
Also Read:Akum Gets CDSCO Panel Nod to Manufacture, Market Glimepiride, Lobeglitazone FDC
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.